Artemisinin-based combination therapy for ... - The Cochrane Library
Artemisinin-based combination therapy for ... - The Cochrane Library
Artemisinin-based combination therapy for ... - The Cochrane Library
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Grande 2005 PER<br />
Methods Trial design: An open-label randomized controlled trial<br />
Follow up: Days 0, 1, 2, 3, 7, 14, 21, 28, 35, 42, 49, 56, and 63 or any other day they<br />
became ill, <strong>for</strong> a clinical assessment and malaria film. PCV measurement day 0, 7, 14<br />
and 63. P. vivax treated with CQ.<br />
Adverse event monitoring: Assessed at each follow-up visit, an adverse event defined as<br />
any unfavourable and unintended sign, symptom or disease temporally associated with<br />
the drug administered. Complete blood count, liver, and renal function tests at days 0<br />
and 7.<br />
Participants Number: 522 randomized<br />
Inclusion criteria: Age 5 to 60 yrs, fever > 37.5 ºC or history of fever in the previous 24<br />
hours, P. falciparum mono-infection 1000 to 200,000/µl<br />
Exclusion criteria: Pregnancy or lactation, severe malaria, any concomitant illness or<br />
underlying disease, contraindication to any of the trial drugs, history of treatment with<br />
mefloquine in the previous 60 days or chloroquine, primaquine or quinine in previous<br />
14 days<br />
Interventions 1. Dihydroartemisinin-piperaquine, fixed dose <strong>combination</strong> (Artekin: Holleykin)<br />
• Total dose: 6.3 mg/kg DHA and 50.4 mg/kg PQP in 3 divided doses, given once<br />
daily <strong>for</strong> 3 days<br />
2. Artesunate plus mefloquine, loose <strong>combination</strong> (Artesunate: Guilin, Lariam: Hoffman<br />
La-Roche)<br />
• AS 4 mg/kg once daily <strong>for</strong> 3 days<br />
• MQ 8 mg/kg once daily <strong>for</strong> 3 days<br />
All doses supervized<br />
Outcomes 1. Day 63 cure rate PCR adjusted and unadjusted<br />
2. P. vivax during follow up<br />
3. Gametocyte prevalence at day 0, 7, 14, 21 and 28<br />
4. Gametocyte development during follow up<br />
5. Adverse events<br />
Not included in this review:<br />
1. Fever clearance<br />
2. Parasite clearance<br />
Notes Country: Peru<br />
Setting: 9 rural health posts<br />
Transmission: Low malaria transmission<br />
Resistance: High CQ and SP resistance<br />
Dates: July 2003 to July 2005<br />
Funding: Directorate-General <strong>for</strong> Development and Cooperation of the Belgian Government<br />
Risk of bias<br />
Item Authors’ judgement Description<br />
Adequate sequence generation? Unclear ’Randomized in blocks of 10’. No further<br />
details given.<br />
<strong>Artemisinin</strong>-<strong>based</strong> <strong>combination</strong> <strong>therapy</strong> <strong>for</strong> treating uncomplicated malaria (Review)<br />
Copyright © 2009 <strong>The</strong> <strong>Cochrane</strong> Collaboration. Published by John Wiley & Sons, Ltd.<br />
56